---
title: Antifungal Drugs
type: content
phase: 1
status: complete
priority: high
tags: [antifungals, azoles, polyenes, echinocandins, amphotericin, fluconazole, voriconazole, candida, aspergillus, mycoses]
created: 2025-11-08
last_modified: 2025-11-08
---

# Antifungal Drugs

## Introduction

Fungal infections range from superficial (skin, nails) to life-threatening systemic mycoses. Antifungal therapy has expanded significantly, offering multiple drug classes with varying spectra, toxicities, and routes of administration. Understanding fungal cell biology and drug mechanisms is essential for effective treatment.

## Core Concepts

### Fungal Cell Structure

**Key differences from mammalian cells**:
- **Cell wall**: Contains chitin, β-glucans (absent in mammals)
- **Cell membrane**: Contains **ergosterol** (vs. cholesterol in mammals)
- These differences are targets for selective toxicity

### Classification of Fungal Infections

**Superficial**: Dermatophytes (tinea), Candida (skin/mucosa)
**Subcutaneous**: Sporotrichosis
**Systemic/Endemic**: Histoplasma, Blastomyces, Coccidioides
**Opportunistic**: Candida, Aspergillus, Cryptococcus, Mucor (immunocompromised)

---

## Polyene Antifungals

### Amphotericin B

**Mechanism of Action**:
- Binds **ergosterol** in fungal cell membrane
- Forms pores → membrane disruption → cell death
- **Fungicidal**
- Also binds cholesterol (mammalian cells) → toxicity

**Spectrum**:
- **Broadest spectrum antifungal**
- Candida (including azole-resistant species)
- Aspergillus
- Cryptococcus
- Endemic mycoses (Histoplasma, Blastomyces, Coccidioides)
- Mucormycosis (drug of choice)
- **NOT active**: Scedosporium, Fusarium (variably susceptible)

**Formulations**:
1. **Conventional amphotericin B deoxycholate** (AmB-D)
2. **Lipid formulations**: Liposomal AmB (L-AmB), AmB lipid complex (ABLC)
   - ↓Nephrotoxicity
   - ↑Cost
   - Preferred when available

**Pharmacokinetics**:
- **IV only** (not absorbed orally)
- Highly protein-bound
- Poor CNS penetration (even with inflammation)
- Long terminal half-life (15 days)
- Hepatic/biliary excretion

**Clinical Uses**:
- **Severe systemic mycoses** (life-threatening)
- **Empiric antifungal** in febrile neutropenia
- **Mucormycosis** (drug of choice)
- **Cryptococcal meningitis** (induction with flucytosine)
- **Endemic mycoses** (severe)
- **Candida** infections (azole-resistant, severe)

**Adverse Effects**:

**Infusion-Related** ("Shake and Bake"):
- **Fever, chills, rigors** (common, cytokine-mediated)
- Headache, myalgias
- Nausea, vomiting
- **Prevention**: Premedicate with acetaminophen, diphenhydramine, ± meperidine
- Slows infusion rate, IV hydration

**Nephrotoxicity** (dose-limiting):
- **Nearly universal** with conventional AmB
- ↑Creatinine, azotemia
- Renal tubular acidosis (Type I)
- **Hypokalemia, hypomagnesemia** (renal wasting)
- Mechanisms: Renal vasoconstriction, direct tubular toxicity
- **Prevention**: IV saline loading, lipid formulations

**Electrolyte Abnormalities**:
- **Hypokalemia** (common, can be severe)
- **Hypomagnesemia**
- Supplement aggressively

**Anemia**:
- ↓Erythropoietin production

**Thrombophlebitis**:
- Administer via central line preferred

**Monitoring**:
- SCr, BUN daily
- Electrolytes (K+, Mg2+) daily
- CBC weekly
- LFTs

**Clinical Pearls**:
1. **Gold standard** for serious fungal infections despite toxicity
2. **Lipid formulations**: Less nephrotoxic, preferred if available
3. **Premedication**: Reduces infusion reactions
4. **Aggressive electrolyte repletion**: K+, Mg2+ commonly needed
5. **Saline loading**: 0.9% NaCl before and after infusion ↓nephrotoxicity

### Nystatin

**Similar structure** to amphotericin B

**Use**:
- **Topical only** (too toxic for systemic use)
- Oral candidiasis (thrush): Swish and swallow suspension
- Cutaneous candidiasis: Topical cream

---

## Azole Antifungals

### Mechanism of Action

- Inhibit fungal **lanosterol 14α-demethylase** (CYP51)
- Block ergosterol synthesis
- Accumulation of toxic sterol intermediates
- **Fungistatic** (generally)

### Classification

**Imidazoles** (topical):
- Clotrimazole, miconazole, ketoconazole (oral use rare due to toxicity)

**Triazoles** (systemic):
- Fluconazole, itraconazole, voriconazole, posaconazole, isavuconazole

---

### Fluconazole (Diflucan)

**Spectrum**:
- **Candida**: C. albicans, C. tropicalis, C. parapsilosis (NOT C. glabrata, NOT C. krusei)
- **Cryptococcus neoformans**
- **Endemic mycoses**: Coccidioides (meningitis)
- **NOT active**: Aspergillus, Mucor

**Pharmacokinetics**:
- **Excellent oral bioavailability** (~90%, IV = PO)
- Minimal protein binding
- **Excellent CNS penetration** (70% of serum levels)
- **Renal excretion** (80% unchanged)
- **Dose adjustment** in renal impairment

**Clinical Uses**:
- **Candida infections**: Candidemia, invasive candidiasis (if susceptible species)
- **Cryptococcal meningitis**: Consolidation and maintenance therapy (after AmB induction)
- **Coccidioides meningitis**
- **Oral/esophageal candidiasis** (HIV/AIDS)
- **Candida prophylaxis**: Neutropenic patients, transplant
- **Vaginal candidiasis**: Single 150 mg dose
- **Tinea** infections (systemic therapy)

**Dosing**:
- Loading dose often used (800 mg → 400 mg daily)
- Adjust for renal function

**Adverse Effects**:
- Generally well-tolerated
- **Hepatotoxicity**: ↑Transaminases (monitor LFTs)
- **GI upset**: Nausea, diarrhea
- **QT prolongation** (rare)
- **Teratogenicity**: High-dose (≥400 mg/day) in 1st trimester → cardiac/skeletal defects
  - **Avoid in pregnancy** (especially 1st trimester)

**Drug Interactions**:
- **CYP2C9, CYP3A4 inhibitor**
- **Warfarin**: ↑INR (reduce warfarin dose 25-50%)
- **Phenytoin**: ↑Phenytoin levels (monitor)
- **Statins**: ↑Statin levels → rhabdomyolysis risk
- **Rifampin**: ↓Fluconazole levels

**Clinical Pearls**:
1. **First-line for Candida** (susceptible species)
2. **Excellent CNS penetration**: Drug of choice for cryptococcal maintenance
3. **IV = PO**: Use oral when possible
4. **Pregnancy Category D**: Avoid, especially high doses
5. **Renal dosing**: Required

---

### Itraconazole (Sporanox)

**Spectrum**:
- **Broader than fluconazole**
- Candida, Aspergillus (less than voriconazole)
- **Endemic mycoses**: Histoplasma, Blastomyces, Coccidioides
- Dermatophytes

**Pharmacokinetics**:
- **Oral** (capsule, solution) and IV
- **Variable oral absorption**: Capsule requires acidic pH (take with food, acidic beverage)
- Solution better absorbed (take on empty stomach)
- **Highly protein-bound** (99%)
- **Poor CNS penetration**
- **Hepatic metabolism** (CYP3A4)
- No renal dose adjustment

**Clinical Uses**:
- **Blastomycosis**: Mild-moderate
- **Histoplasmosis**: Mild-moderate, maintenance
- **Aspergillosis**: Second-line (voriconazole preferred)
- **Onychomycosis** (nail infections): Pulse dosing
- **Sporotrichosis**: Cutaneous, lymphocutaneous

**Adverse Effects**:
- **Negative inotropic effects**: **Contraindicated in heart failure**
- **Hepatotoxicity**: Monitor LFTs
- **Hypokalemia**
- **Edema**
- **GI upset**

**Drug Interactions**:
- **Extensive**: CYP3A4 substrate and inhibitor
- **Contraindicated with**: Certain antihistamines (terfenadine, astemizole), cisapride, quinidine, pimozide
- **Proton pump inhibitors, H2 blockers**: ↓Absorption (capsule)
- **Statins, warfarin**: ↑Levels

**Monitoring**:
- LFTs
- Drug levels (therapeutic drug monitoring available)

**Clinical Pearls**:
1. **Endemic mycoses**: First-line for mild-moderate disease
2. **Heart failure**: Contraindicated (negative inotropy)
3. **Absorption issues**: Capsule needs acid; solution better
4. **Onychomycosis**: Pulse therapy (1 week/month)

---

### Voriconazole (Vfend)

**Spectrum**:
- **Aspergillus** (drug of choice for invasive aspergillosis)
- Candida (including fluconazole-resistant species)
- **Scedosporium, Fusarium** (resistant to amphotericin)
- Endemic mycoses
- **NOT active**: Mucormycosis (contraindicated; enhances growth)

**Pharmacokinetics**:
- **IV or PO** (excellent oral bioavailability ~96%)
- **Non-linear pharmacokinetics** (saturable metabolism)
- **Hepatic metabolism** (CYP2C19, CYP3A4, CYP2C9)
- **Genetic polymorphisms**: CYP2C19 affects levels (15-20% poor metabolizers)
- **Excellent CNS penetration**

**Clinical Uses**:
- **Invasive aspergillosis** (first-line)
- **Candida** infections (including fluconazole-resistant)
- **Scedosporium, Fusarium** infections
- **CNS fungal infections** (good penetration)

**Dosing**:
- Loading dose required (IV or PO)
- Therapeutic drug monitoring recommended (target trough 1-5.5 mcg/mL)

**Adverse Effects**:
- **Visual disturbances** (30%): Blurred vision, photophobia, color changes
  - Usually transient, within 30 min of dose, resolves
- **Hepatotoxicity**: ↑Transaminases (monitor LFTs weekly initially)
- **Photosensitivity**: Severe sunburn, squamous cell carcinoma (long-term)
- **Hallucinations** (dose-related)
- **QT prolongation**
- **Periostitis**: Bone pain, ↑fluoride, ↑alkaline phosphatase (long-term)

**Drug Interactions**:
- **Extensive**: CYP2C19, CYP3A4 substrate and inhibitor
- **Contraindicated with**: Rifampin, rifabutin, carbamazepine, long-acting barbiturates, ritonavir
- **Warfarin, statins, tacrolimus, cyclosporine**: ↑Levels

**Contraindications**:
- **Mucormycosis**: Do NOT use (promotes growth)

**Monitoring**:
- **Therapeutic drug monitoring**: Trough levels
- **LFTs**: Weekly initially, then periodic
- **Visual function**: Baseline and if symptoms

**Clinical Pearls**:
1. **First-line for invasive aspergillosis**
2. **Visual disturbances**: Common, warn patients, usually transient
3. **TDM**: Recommended due to non-linear kinetics
4. **Mucormycosis**: Absolutely avoid
5. **Photosensitivity**: Sunscreen, avoid excessive sun exposure

---

### Posaconazole (Noxafil)

**Spectrum**:
- **Broadest azole**
- Aspergillus, Candida
- **Mucormycosis** (active, unlike voriconazole)
- Endemic mycoses
- Fusarium, Scedosporium

**Formulations**:
- **Oral suspension**: Variable absorption (take with fatty food)
- **Delayed-release tablet**: Better, more consistent absorption
- **IV formulation**: Available

**Clinical Uses**:
- **Prophylaxis** in high-risk patients: Neutropenic, GVHD, hematologic malignancies
- **Salvage therapy**: Aspergillosis, mucormycosis (refractory/intolerant to first-line)

**Adverse Effects**:
- Similar to other azoles
- **QT prolongation**
- Hepatotoxicity

**Clinical Pearls**:
1. **Mucormycosis**: Active (unlike voriconazole)
2. **Prophylaxis**: Common use in high-risk hematology patients
3. **Tablet preferred**: Better absorption than suspension

---

### Isavuconazole (Cresemba)

**Spectrum**:
- Aspergillus, Candida
- **Mucormycosis**

**Advantages**:
- **Fewer drug interactions** than voriconazole
- **No visual disturbances**
- Well-tolerated

**Clinical Uses**:
- **Invasive aspergillosis** (alternative to voriconazole)
- **Mucormycosis**

**Clinical Pearl**: Newer alternative to voriconazole with better tolerability

---

## Echinocandins

**Drugs**: Caspofungin, Micafungin, Anidulafungin

### Mechanism of Action

- Inhibit **β-1,3-D-glucan synthase**
- Block cell wall synthesis (glucan component)
- **Fungicidal** against Candida
- **Fungistatic** against Aspergillus
- **Unique mechanism**: No cross-resistance with azoles/polyenes

### Spectrum

- **Candida** (including azole-resistant species, C. glabrata, C. krusei)
- **Aspergillus** (second-line)
- **NOT active**: Cryptococcus, endemic mycoses, Mucor

### Pharmacokinetics

- **IV only** (no oral formulation)
- Highly protein-bound
- **Hepatic metabolism** (not CYP-mediated)
- **No renal dose adjustment**

### Clinical Uses

- **Invasive candidiasis/candidemia** (first-line in many centers)
- **Empiric antifungal** in febrile neutropenia (alternative to AmB)
- **Aspergillosis**: Salvage therapy or combination with voriconazole
- **Candida prophylaxis**: High-risk patients

### Adverse Effects

- **Very well tolerated** (major advantage)
- **Phlebitis** (IV site)
- ↑Liver enzymes (mild)
- **Histamine release**: Flushing, rash (infusion-related, rare)

### Drug Interactions

- **Minimal** (not CYP-mediated metabolism) - major advantage
- **Cyclosporine**: ↑Caspofungin levels, ↑LFTs (avoid combination)
- **Rifampin**: ↓Caspofungin levels (increase caspofungin dose)

### Individual Agents

**Caspofungin** (Cancidas):
- First echinocandin
- Loading dose required

**Micafungin** (Mycamine):
- No loading dose
- Approved for pediatrics, prophylaxis

**Anidulafungin** (Eraxis):
- No hepatic metabolism (chemical degradation)
- No dose adjustment in hepatic/renal impairment

### Clinical Pearls

1. **First-line for Candida**: Especially ICU, hemodynamically unstable
2. **Well-tolerated**: Excellent safety profile
3. **Minimal drug interactions**: Advantage over azoles
4. **IV only**: Limitation (no oral step-down)
5. **Active against azole-resistant Candida**: C. glabrata, C. krusei

---

## Flucytosine (5-FC, Ancobon)

### Mechanism of Action

- Prodrug converted to **5-fluorouracil (5-FU)** by fungal cytosine deaminase
- 5-FU interferes with DNA/RNA synthesis
- **Fungistatic**

### Spectrum

- **Cryptococcus**
- **Candida** (variable)
- Chromoblastomycosis

### Clinical Uses

- **Cryptococcal meningitis**: **Combination with amphotericin B** (induction)
  - Synergistic effect
  - ↓Resistance (never use alone)
- Candida (rarely used)

### Pharmacokinetics

- **Oral** (well absorbed)
- Minimal protein binding
- **Excellent CNS penetration**
- **Renal excretion** (dose adjustment required)

### Adverse Effects

- **Bone marrow suppression**: Dose-related, reversible
  - Leukopenia, thrombocytopenia, anemia
  - **Monitor CBC closely**
- **GI upset**: Nausea, vomiting, diarrhea
- **Hepatotoxicity**: ↑Transaminases

**Mechanism of Toxicity**:
- Conversion to 5-FU by gut flora (mammalian cells lack cytosine deaminase)
- ↑Toxicity with renal impairment (accumulation)

### Monitoring

- **Drug levels**: Target 25-100 mcg/mL (avoid >100 mcg/mL)
- **CBC**: Frequently (2-3×/week)
- **LFTs**
- **Renal function**

### Clinical Pearls

1. **Never use alone**: Rapid resistance
2. **Combination with AmB**: Synergistic for cryptococcal meningitis
3. **Monitor levels and CBC**: Prevent bone marrow toxicity
4. **Renal dosing**: Essential

---

## Topical Antifungals

### Azoles

- **Clotrimazole, miconazole, econazole, ketoconazole** (topical)
- **Uses**: Dermatophyte infections (tinea), cutaneous candidiasis, vaginal candidiasis

### Allylamines

- **Terbinafine** (Lamisil): Cream and oral
- **Naftifine**

**Mechanism**: Inhibit squalene epoxidase (ergosterol synthesis)

**Uses**:
- **Topical**: Tinea (athlete's foot, jock itch, ringworm)
- **Oral terbinafine**: Onychomycosis (nail infections)
  - More effective than azoles for dermatophytes
  - 3-6 months therapy (fingernails 6 weeks, toenails 12 weeks)

**Adverse Effects (oral terbinafine)**:
- **Hepatotoxicity**: Monitor LFTs
- **Taste disturbances** (ageusia)
- Rash
- GI upset

### Ciclopirox

- Topical antifungal
- Tinea, cutaneous candidiasis

### Griseofulvin

- **Oral antifungal** (older agent)
- **Mechanism**: Inhibits microtubule function → disrupts mitosis
- **Uses**: Dermatophyte infections (tinea capitis, extensive tinea corporis)
- **Adverse effects**: Headache, GI upset, photosensitivity, teratogenic
- **Drug interactions**: CYP450 inducer
- **Largely replaced by terbinafine**

---

## Clinical Approach to Fungal Infections

### Candidemia / Invasive Candidiasis

**First-line**:
- **Echinocandin** (caspofungin, micafungin, anidulafungin)

**Alternatives**:
- Fluconazole (if stable, not critically ill, susceptible species)
- Amphotericin B (lipid formulation)

**Duration**: 14 days after documented clearance and resolution of symptoms

### Invasive Aspergillosis

**First-line**:
- **Voriconazole**

**Alternatives**:
- Isavuconazole
- Amphotericin B (lipid formulation)
- Posaconazole (salvage)

**Combination therapy**: Consider voriconazole + echinocandin in severe cases

### Mucormycosis

**First-line**:
- **Amphotericin B** (lipid formulation, high-dose)

**Adjunct**:
- **Surgical debridement** (essential)
- Posaconazole or isavuconazole (salvage or step-down)

**Avoid**: Voriconazole (promotes growth)

### Cryptococcal Meningitis

**Induction** (2 weeks):
- **Amphotericin B + flucytosine**

**Consolidation** (8 weeks):
- **Fluconazole** 400 mg daily

**Maintenance** (6-12 months in HIV):
- **Fluconazole** 200 mg daily

### Endemic Mycoses (Histoplasmosis, Blastomycosis, Coccidioidomycosis)

**Mild-Moderate**:
- **Itraconazole**

**Severe**:
- **Amphotericin B** (induction) → itraconazole (consolidation/maintenance)

---

## Key Takeaways

1. **Amphotericin B**: Broadest spectrum, gold standard for severe mycoses, nephrotoxic
2. **Fluconazole**: First-line for Candida (susceptible), excellent CNS penetration
3. **Voriconazole**: First-line for invasive aspergillosis, visual disturbances common
4. **Echinocandins**: First-line for invasive candidiasis, well-tolerated, IV only
5. **Posaconazole/Isavuconazole**: Active against mucormycosis (unlike voriconazole)
6. **Flucytosine**: Never use alone, combination with AmB for cryptococcal meningitis
7. **Itraconazole**: Endemic mycoses, heart failure contraindication
8. **Azoles**: Extensive drug interactions (CYP inhibition)
9. **Terbinafine**: Oral therapy for onychomycosis
10. **Resistance patterns**: C. krusei (fluconazole-resistant), C. glabrata (azole-resistant) - use echinocandin

---

## References

1. Katzung's Basic & Clinical Pharmacology, 15th Edition
2. Goodman & Gilman's Pharmacological Basis of Therapeutics, 14th Edition
3. IDSA Clinical Practice Guideline for Candidiasis. Clin Infect Dis. 2016.
4. IDSA/ATS Clinical Practice Guideline for Aspergillosis. Clin Infect Dis. 2016.
5. Perfect JR, et al. Clinical Practice Guidelines for Cryptococcal Disease. Clin Infect Dis. 2010.
